Strive Health, the national leader in value-based kidney care, generated net savings in 100% of its Kidney Contracting Entities (KCEs) in the Comprehensive Kidney Care Contracting (CKCC) program for the 2022 performance year — the highest per-beneficiary savings across all organizations participating in the model. The CKCC model was designed by the Centers for Medicare & Medicaid Services (CMS) to improve outcomes and reduce costs for Medicare beneficiaries with chronic kidney disease (CKD) through enhanced payment mechanisms, increased patient engagement and added care resources.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024274604/en/
Strive Health’s high-touch, value-based kidney care led to the highest per-beneficiary savings in Medicare’s Comprehensive Kidney Care Contracting (CKCC) program for 2022. (Photo: Business Wire)
“Strive’s performance in CMS’s CKCC program demonstrates the commitment of our nephrology partners to make the shift to value-based care,” said Chris Riopelle, Co-Founder and CEO at Strive. “We are proud to work together to change the kidney care paradigm, and we will continue to find ways to better understand and address head-on the unique challenges that people with kidney disease face.”
In the 2022 performance year, Strive generated approximately $12 million in savings for Medicare. The CKCC model overall generated $63 million in total savings for CMS. All KCE results have been published on the Center for Medicare and Medicaid Innovation website.
CKCC is part of the Kidney Care Choices (KCC) Model, which puts nephrologists at the center and includes diverse incentive payments for providers to manage care of Medicare beneficiaries with CKD and end-stage kidney disease (ESKD) to delay the onset of dialysis and incentivize kidney transplantation.
Strive has built its model around bringing high-touch care to the kidney disease population to identify patients earlier, prioritize the right care at the right time and drive better outcomes to avoid progression to ESKD and in-center dialysis. The company helps drive resources to identify and care for patients developing kidney failure so that fewer receive dialysis in dialysis centers, the number of kidney transplants is increased and patients can live longer, healthier lives through its participation in the CKCC program.
Strive currently operates KCEs in California, Illinois, Indiana, Michigan, Missouri, New Jersey, New York, Ohio, Pennsylvania and Texas and has more than doubled its footprint in these states since 2022. To learn more about Strive Health and how it supports chronic kidney disease patients through the CKCC model, visit https://strivehealth.com/.
ABOUT STRIVE HEALTH
Strive Health is the nation’s leader in value-based kidney care and partner of choice for innovative healthcare payors and providers. Using a unique combination of technology-enabled care interventions and seamless integration with local providers, Strive forms an integrated care delivery system that supports the entire patient journey from chronic kidney disease (CKD) to end-stage kidney disease (ESKD). To help patients, Strive partners with commercial and Medicare Advantage payors, Medicare, health systems and physicians through flexible value-based payment arrangements, including risk-based programs. Strive serves over 121,000 people with CKD and ESKD across 50 states and partners with over 6,500 providers. Strive’s case management and population health programs are accredited by the National Committee for Quality Assurance (NCQA), and its technology platform, CareMultiplier™, is certified by HITRUST. To learn more, visit StriveHealth.com.
|
The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of the Centers for Medicare & Medicaid Services. The authors assume responsibility for the accuracy and completeness of the information contained in this document. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024274604/en/